Michael Kubek, PhD

Founder and Chief Executive Officer

Dr. Kubek became the Chief Executive Officer of MVK Pharmaceuticals from its inception in 2017 as a spin-off from his DoD grant at Indiana University’s School of Medicine to treat suicidal ideation with major depression using Thyrotropin-releasing Hormone (TRH) nanoparticles.  He has served as an Associate Professor of Anatomy and Neurobiology at the Indiana University School of Medicine since 1978 and retired from the military as an US Army Reserve Chemical Corps Officer from 1974 - 1980. Dr. Kubek is one of the initial investigators to characterize and map MVK’s initial molecule, Thyrotropin-releasing Hormone (TRH), in the human CNS and has extensive experience in laboratory research where he has authored and co-authored more than 30 articles and book chapters in research including: CDNA cloning, in situ hybridization, immunocytochemical localization, quantitation, characterization, metabolism, and receptor activity of hypothalamic and extra hypothalamic neuroactive peptides and their effects on neuroendocrine function, neurologic and affective disorders and epilepsy.

​

Dr. Kubek received a Biology and Chemistry BS degree and a Endocrinology MS degree from University of Dayton, followed by a PhD from the University of Rochester School of Medicine and a Postdoctoral Fellowship at Northwestern University School of Medicine.